pharmaphorum

JANUARY 5, 2023

Stéphane Bancel, chief executive officer at Moderna, said: “With this acquisition, we obtain best-in-class tools for cell-free synthesis and amplification of plasmid DNA, a key building block in mRNA manufacturing.”. The post Boost for mRNA as Moderna to acquire OriCiro for $85 million appeared first on.

Gene Sequencing 97

Gene Sequencing DNA Vaccination Vaccine 97

pharmaphorum

JUNE 23, 2022

Systemic administration of gene-editing drugs would avoid that process with an “off-the-shelf” option for a one-shot, potentially curative treatment for diseases associated with genetic mutations. billion agreement that started in 2020.

Gene Editing 97

Gene Editing In-Vivo Gene Sequencing Gene 97

pharmaphorum

AUGUST 10, 2021

million for the one-shot therapy, which was approved in 2019 but faced a delayed launch because of manufacturing problems. At the time, the biotech said it would also reduce staff and restructure its European business in order to focus on “priority” markets. bluebird had set an initial price of $1.8

Gene Therapy 135

Gene Therapy Gene Marketing Genetic Disease 135

pharmaphorum

OCTOBER 12, 2022

The neoantigens are selected based on gene sequencing of either a tumour biopsy or a blood sample, with an individual vaccine tailored to the patient manufactured and administered in a matter of weeks.

Vaccine 105

Vaccine Vaccination Gene Sequencing RNA 105

Roots Analysis

FEBRUARY 21, 2022

Since the introduction of a gene sequencing method by Frederick Sanger in 1977, the field of genomic data collection and analysis has evolved significantly. Advancement in DNA sequencing technologies have resulted in noteworthy developments in various healthcare-related research fields, such as diagnostics and personalized medicine.

Marketing 52

Marketing Gene Sequencing DNA Genomics 52

Roots Analysis

FEBRUARY 23, 2022

For more details on this emerging domain, check out the following report : Next Generation Sequencing (NGS) Library Preparation Kits. Our Social Media Platform. Web: [link]. LinkedIn: [link]. Twitter: [link].

Genetics 52

Genetics DNA RNA Reagent 52

pharmaphorum

OCTOBER 1, 2021

.” In its prospectus, Oxford Nanopore said the proceeds from the IPO would be used to increase R&D investment, double its commercial team within the next 18 months, and build up its manufacturing and business development capacity.

Marketing 52

Marketing Genomics Genome Business Development 52